Sugi Predict

Sugi Predict / Compounds / SCHEMBL3200744

SCHEMBL3200744

SCHEMBL3200744

Cc1ccc(NC(=O)Nc2ccc(C)c(CN3CCN(C(=O)O)CC3)c2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ CNR2 P34972 3/20 0.44
▸ CNR1 P21554 2/20 0.44
▸ ACKR3 P25106 3/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.42
▸ DDX3X O00571 1/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ FAAH O00519 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ KIT P10721 1/20 0.40
▸ BLK P51451 1/20 0.40
▸ DDR1 Q08345 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206500 0.90 NPSR1 (0.48) MEN1KMT2AACKR3NPSR1DDX3X
SCHEMBL3215364 0.90 KCNQ3 (0.45) ACKR3NPSR1DDX3XNPC1POLB
SCHEMBL403301 0.90 MEN1 (0.43) MEN1KMT2ACNR2CNR1ACKR3
SCHEMBL4760966 0.88 NAMPT (0.46) MEN1KMT2AFAAHKITDDR2
SCHEMBL3208049 0.87 AR (0.39) CNR2NPSR1DDX3XNPC1POLB
SCHEMBL3196669 0.85 FAAH (0.47) MEN1KMT2AACKR3NPC1POLB
SCHEMBL3198046 0.84 ACKR3 (0.52) ACKR3NPC1POLBFAAHRAB9A
SCHEMBL3210260 0.83 RORC (0.44) NPSR1DDX3XNPC1POLBALDH1A1
SCHEMBL3211043 0.83 RORC (0.43) NPSR1DDX3XNPC1POLBALDH1A1
SCHEMBL3206886 0.82 RORC (0.61) ACKR3NPSR1NPC1RORCDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
EP-2862859-B1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2018-07-25 — — EP disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-9150564-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2015-10-06 — — US disclosed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US disclosed
US-8871769-B2 Ureas and their use in the treatment of heart failure CYTOKINETICS, INC. (US) 2014-10-28 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 MEN1 4505/4885KMT2A 3674/4885CNR2 4534/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MEN1 4319/4885KMT2A 4052/4885CNR2 4365/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 MEN1 4745/4885KMT2A 2999/4885CNR2 4636/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MEN1 4319/4885KMT2A 4052/4885CNR2 4365/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 MEN1 4493/4885KMT2A 4149/4885CNR2 4677/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 MEN1 4319/4885KMT2A 4052/4885CNR2 4365/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885CNR2 4483/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 MEN1 4493/4885KMT2A 4149/4885CNR2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.